viewSilence Therapeutics PLC

Silence Therapeutics given access to genetic database in its bid to find new breakthrough treatments

Genomics England has whole sequencing data on 100,000 genomes

Code to life: a genome is an organism’s complete set of DNA, including all of its genes

Silence Therapeutics PLC (LON:SLN) has been given access to part of a genetic database as it bids to find treatments for rare diseases and ailments.

Genomics England has whole sequencing data on 100,000 genomes.

A genome is an organism’s complete set of DNA, including all of its genes. Each genome contains the information needed to build and maintain that organism.

It is the key to understanding how people differ genetically and therefore how they might respond to different medicines.

Data mining exercise 

In the case of Silence, an expert in silencing disease-associated genes, having access to the database will help in its drug development effort.

Under the terms of the deal with Genomics England, Silence will “data mine” a subset of the information to focus on rare diseases and cardio-metabolic illnesses.

It wants to find disease-modifying target genes best suited to its unique technology.

The exercise should also help with “patient stratification” (dividing them into groups and sub-groups) and recruitment as the company develops its RNAi product candidates.

“This key collaboration will help us increase innovation in our target gene choices and will also be attractive to potential partners as we explore a variety of business development opportunities," said Silence chief executive, Dr David Horn Solomon.

Quick facts: Silence Therapeutics PLC

Price: 451 GBX

Market: AIM
Market Cap: £373.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...



Market Report: FTSE 100 retreats as UK employment tumbles

Headlines from the Proactive UK newsroom. The FTSE100 was on the back foot as the new job numbers highlighted how business is suffering due to the pandemic. The blue chip-index shed 60 to 6,232. People on UK payrolls fell by 649,000 between March and June, according to the government....

3 weeks, 3 days ago

2 min read